A team of biomechanical engineers at the University of New South Wales, working with a colleague from Queensland University of Technology and cardiac surgeons at St Vincent’s Hospital, Sydney, has developed an artificial human heart left ventricle (LV) that can be used for training heart surgeons and other doctors.
Drugs for the K-Ras oncogene inspire an approach for targeting the GTPases, a family of enzymes whose dysfunction can lead to Parkinson’s and many other diseases.
UCSF scientists have discovered how to target a class of molecular switches called GTPases that are involved in a myriad of diseases from Parkinson’s to cancer and have long been thought to be “undruggable.”
Because of their slippery exteriors, the GTPases have remained largely out of reach of modern drug discovery, with the exception of the notorious cancer-causing GTPase called K-Ras.
The foundation hopes to prevent extinctions, and obtain the necessary biological material to safeguard genetic diversity.
Already backed by a confirmed $50 million in funding, its goal is to halt the extinction crisis through three key conservation focus points.
The Colossal Foundation’s first key…
Who ever said you can’t save a few species on the way to de-extincting a mammoth?
As artificial intelligence advances, its uses and capabilities in real-world applications continue to reach new heights that may even surpass human expertise.
Official website for Osaka Metropolitan University. Established in 2022 through the merger of Osaka City University and Osaka Prefecture University.
Researchers from the Color and Food Quality group at the Faculty of Pharmacy, University of Seville, in partnership with Dr. Marina Ezcurra’s team at the University of Kent (UK), have demonstrated that the carotenoid phytoene extends the lifespan of the nematode Caenorhabditis elegans. Additionally, it delays the onset of paralysis linked to amyloid plaque formation in an Alzheimer’s disease model.
Specifically, increases in longevity of between 10 and 18.6% and decreases in the proteotoxic effect of plaques of between 30 and 40% were observed. The studies, which form part of Ángeles Morón Ortiz’s doctoral thesis, tested pure phytoene and extracts rich in this carotenoid obtained from microalgae.
According to Dr. Paula Mapelli Brahm, “These are very exciting preliminary results, so we are looking for funding to continue this line of research and to find out by what mechanisms these effects are produced.”
The Advanced Research Projects Agency for Health (ARPA-H) has awarded $45 million to rapidly develop sense-and-respond implant technology that could slash U.S. cancer-related deaths by more than 50%.
Announced today, the award to a multi-institutional team of researchers, including Carnegie Mellon University, will fast-track development and testing of a new approach to cancer treatment that aims to dramatically improve immunotherapy outcomes for patients with ovarian, pancreatic, and other difficult-to-treat cancers.
Source: Brandon Martin/Rice University. The “hybrid advanced molecular manufacturing regulator,” or HAMMR, a “closed-loop,” drug-producing implant smaller than an adult’s finger is being developed to treat ovarian, pancreatic, and other difficult-to-treat cancers. The implant, which is small enough to be implanted with minimally-invasive surgery, will be able to continuously monitor a patient’s cancer and adjust their immunotherapy dose in real time.